Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation

Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation

Cancer cells exploit immune checkpoint pathways, such as PD-1/PD-L1, to evade elimination by the immune system. Here, the authors demonstrate that TMUB1 regulates post-translational modifications of PD-L1 and that targeting the TMUB1/PD-L1 interaction promotes anti-tumour T cells responses

Bibliographic Details
Main Authors: Chengyu Shi, Ying Wang, Minjie Wu, Yu Chen, Fangzhou Liu, Zheyuan Shen, Yiran Wang, Shaofang Xie, Yingying Shen, Lingjie Sang, Zhen Zhang, Zerui Gao, Luojia Yang, Lei Qu, Zuozhen Yang, Xinyu He, Yu Guo, Chenghao Pan, Jinxin Che, Huaiqiang Ju, Jian Liu, Zhijian Cai, Qingfeng Yan, Luyang Yu, Liangjing Wang, Xiaowu Dong, Pinglong Xu, Jianzhong Shao, Yang Liu, Xu Li, Wenqi Wang, Ruhong Zhou, Tianhua Zhou, Aifu Lin
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-34346-x

Internet

https://doi.org/10.1038/s41467-022-34346-x

Similar Items